Laddar...
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
BACKGROUND: Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate...
Sparad:
| I publikationen: | Clin Med Insights Oncol |
|---|---|
| Huvudupphovsmän: | , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Libertas Academica
2016
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4933532/ https://ncbi.nlm.nih.gov/pubmed/27398042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S38335 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|